Both journals are anchored in large scientific societies and serve basically the same medical , physical and biological community and at the same scientific level ; the two journals are in the most recent Impact Factor list ranked almost back to back , indicating an equal importance and contribution to science .
Radiotherapy and Oncology is more than a scientific journal , it also serves other purpose s such as facilitate education through ( educational ) review s and improving the st and ard of care by bringing forward guidelines for conduct of radiotherapy .
Finally , the journal also tries to maintain a communication platform between the science produced by the membership of ESTRO and therefore it brings papers frommembers in the different European countries , sometimes at the expense of ultimate scientific quality , but with the underst and ing that it is important that the entire ESTRO membership gets access and opportunity to publish in a high ranked journal .
ESTRO , the European Society for Therapeutic Radiation Oncology , or with its new name European Society for Radiation Oncology , is a scientific society .
It means that the prime aim of ESTRO is to bring to bring people together on an individual basis who have a common interest in improving the scientific conduct of radiotherapy and cancer treatment in Europe by ensuring that proper radiotherapy is available in the multidisciplinary treatment of cancer and applied with the right indication and with the most optimal technique .
One of the main aims of this endeavour was to create a platform for scientific exchange through meetings and through the establishment of a scientific journal [ 1 ] .
Thus Radiotherapy and Oncology was launched shortly after the foundation of ESTRO and has become the society ’s prime vehicle for scientific communication by serving ESTRO members through almost the entire 30 years of the society ’s existence .
The aim was to create a peer review ed high quality international journal and that aim has indeed been fulfilled . ‘ ‘
Image-guided intensity-modulated radiotherapy (IG-IMRT) for biliary adenocarcinomas: Initial clinical results.
PURPOSE Biliary tract lesions are comparatively rare neoplasms , with ambiguous indications for radiotherapy . The specific aim of this study was to report the clinical results of a single-institution biliary tract series treated with modern radiotherapeutic techniques , and detail results using both conventional and image-guided intensity-modulated radiation therapy ( IG-IMRT ) . METHODS AND MATERIAL S From 2001 to 2005 , 24 patients with primary adenocarcinoma of the biliary tract ( gallbladder and extrahepatic bile ducts ) were treated by IG-IMRT .  To compare outcomes , data from a sequential series of 24 patients treated between 1995 and 2005 with conventional radiotherapy ( CRT ) techniques  were collected as a comparator set . Demographic and treatment parameters were collected . Endpoints analyzed included treatment-related acute toxicity and survival . RESULTS Median estimated survival for all patients completing treatment was 13.9 months . A statistically significant higher mean dose was given to patients receiving IG-IMRT compared to CRT , 59 vs. 48Gy . IG-IMRT and CRT cohorts had a median survival of 17.6 and 9.0 months , respectively . Surgical resection was associated with improved survival . Two patients ( 4 % ) experienced an RTOG acute toxicity score>2 . The most commonly reported GI toxicities ( RTOG Grade 2 ) were nausea or diarrhea requiring oral medication , experienced by 46 % of patients . CONCLUSION This series presents the first clinical outcomes of biliary tract cancers treated with IG-IMRT . In comparison to a cohort of patients treated by conventional radiation techniques , IG-IMRT was feasible for biliary tract tumors , warranting further investigation in prospect i ve clinical trials
Both journals are anchored in large scientific societies and serve basically the same medical , physical and biological community and at the same scientific level ; the two journals are in the most recent Impact Factor list ranked almost back to back , indicating an equal importance and contribution to science .
Radiotherapy and Oncology is more than a scientific journal , it also serves other purpose s such as facilitate education through ( educational ) review s and improving the st and ard of care by bringing forward guidelines for conduct of radiotherapy .
Finally , the journal also tries to maintain a communication platform between the science produced by the membership of ESTRO and therefore it brings papers frommembers in the different European countries , sometimes at the expense of ultimate scientific quality , but with the underst and ing that it is important that the entire ESTRO membership gets access and opportunity to publish in a high ranked journal .
ESTRO , the European Society for Therapeutic Radiation Oncology , or with its new name European Society for Radiation Oncology , is a scientific society .
It means that the prime aim of ESTRO is to bring to bring people together on an individual basis who have a common interest in improving the scientific conduct of radiotherapy and cancer treatment in Europe by ensuring that proper radiotherapy is available in the multidisciplinary treatment of cancer and applied with the right indication and with the most optimal technique .
One of the main aims of this endeavour was to create a platform for scientific exchange through meetings and through the establishment of a scientific journal [ 1 ] .
Thus Radiotherapy and Oncology was launched shortly after the foundation of ESTRO and has become the society ’s prime vehicle for scientific communication by serving ESTRO members through almost the entire 30 years of the society ’s existence .
The aim was to create a peer review ed high quality international journal and that aim has indeed been fulfilled . ‘ ‘